Hip disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years, no gender limit. 2. The subjects had indications of total hip replacement surgery (primary or secondary hip osteoarthritis, avascular necrosis of femoral head, femoral neck fracture, etc.). 3. The subject received total hip replacement for the first time. 4. The subject or his legal agent is informed of the nature of the study and agrees to participate in all terms of the study, and agrees to participate in the study by signing the informed consent approved by the Ethics Committee.
Exclusion criteria
Exclusion criteria: 1. BMI > 35; 2. Postoperative hip instability or gait abnormalities (e.g. paralysis, myolysis, or abductor weakness) due to neuromuscular dysfunction; 3. Active infection of the hip joint or other parts of the body; 4. The patient is known to have severe osteoporosis, metabolic bone disease, and radioactive bone disease around the hip joint; 5. The patient is known to have a history of allergy to one or more implanted materials; 6. Coagulation dysfunction, which cannot be corrected or has bleeding tendency; 7. Pregnant or planning to become pregnant during the study period; 8. Participated in other drug or medical device clinical trials within 30 days prior to screening; 9. The investigator judged that the patient had poor compliance and could not complete the study as required; 10. Other circumstances considered by the investigator to be inappropriate for participation in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The accuracy of acetabular cup placement; | — |
Secondary
| Measure | Time frame |
|---|---|
| The deviation of acetabular cup anteversion;The deviation of acetabular cup inclination;Lower limb length difference;Acetabular cup size deviation;Combined offset;Operation time;Harris Hip Joint Function Scale; | — |
Countries
China